Source:http://linkedlifedata.com/resource/pubmed/id/16327241
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
12
|
pubmed:dateCreated |
2005-12-5
|
pubmed:abstractText |
The proclamation of April 2002 of a Ministry of Health, Labor and Welfare ordinance has enabled doctors to prescribe drugs for an outpatient without a limit on the length of prescription terms except for a few drugs. There is a concern that the prescription-term deregulation could cause careless drug therapy management in order to extend the interval between patient hospital visits. The purpose of this study is to make pre- and post-deregulation comparisons of two items, prescription terms and implementation of clinical examination that complied with package-insert precautions, and to discuss the approaches to increase safety. Prescription terms have lengthened progressively. In the pre-regulation period of January to March 2002, the mean prescription term was 19.9 days; in the post-regulation period of July to September 2002, it was 24.9 days; and in July to September 2003, 28.6 days. Even for anti-tumor agents, there were prescriptions over 90 days after deregulation. There was no significant difference between the pre- and post-deregulation compliance ratios for the package-insert precautions in eight drugs of investigated nine. However, one case had a delay in detection of liver dysfunction, which was caused by deviation from the once-a-month testing indicated in the package-insert precautions for prolonged prescription terms. The evidence suggested that the deregulation led to negligent drug therapy management. To assure safe therapy, the following should be addressed: first, sufficient function of a computerized prescriber order entry system and second, creation of a new framework with pharmacists' active involvement such as collaborative therapy management with physicians.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0031-6903
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
125
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
959-69
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:16327241-Ambulatory Care,
pubmed-meshheading:16327241-Drug Labeling,
pubmed-meshheading:16327241-Drug Prescriptions,
pubmed-meshheading:16327241-Drug Therapy,
pubmed-meshheading:16327241-Drug Toxicity,
pubmed-meshheading:16327241-Fees, Medical,
pubmed-meshheading:16327241-Humans,
pubmed-meshheading:16327241-Japan,
pubmed-meshheading:16327241-Time Factors
|
pubmed:year |
2005
|
pubmed:articleTitle |
Impact of prescription-term deregulation with revised medical service fees on drug therapy management.
|
pubmed:affiliation |
Department of Pharmacy, Kagawa University Hospital, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa 761-0793, Japan.
|
pubmed:publicationType |
Journal Article,
Comparative Study
|